TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01115868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prevascar 5ng
Description: 100uL of 5ng/100uL Prevascar per linear centimetre wound margin injected intradermally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prevascar 5ng
Description: 100uL of 5ng/100uL Prevascar per linear centimetre wound margin injected intradermally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prevascar 5ng
Description: 100uL of 5ng/100uL Prevascar per linear centimetre wound margin injected intradermally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prevascar 5ng
Description: 100uL of 5ng/100uL Prevascar per linear centimetre wound margin injected intradermally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prevascar 25ng
Description: • 100uL of 25ng/100uL Prevascar per linear centimetre wound margin injected intradermally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prevascar 25ng
Description: • 100uL of 25ng/100uL Prevascar per linear centimetre wound margin injected intradermally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prevascar 25ng
Description: • 100uL of 25ng/100uL Prevascar per linear centimetre wound margin injected intradermally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prevascar 25ng
Description: • 100uL of 25ng/100uL Prevascar per linear centimetre wound margin injected intradermally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prevascar 100ng
Description: • 100uL of 100ng/100uL Prevascar per linear centimetre wound margin injected intradermally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prevascar 100ng
Description: • 100uL of 100ng/100uL Prevascar per linear centimetre wound margin injected intradermally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prevascar 100ng
Description: • 100uL of 100ng/100uL Prevascar per linear centimetre wound margin injected intradermally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prevascar 100ng
Description: • 100uL of 100ng/100uL Prevascar per linear centimetre wound margin injected intradermally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prevascar 250ng
Description: • 100uL of 250ng/100uL Prevascar per linear centimetre wound margin injected intradermally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prevascar 250ng
Description: • 100uL of 250ng/100uL Prevascar per linear centimetre wound margin injected intradermally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prevascar 250ng
Description: • 100uL of 250ng/100uL Prevascar per linear centimetre wound margin injected intradermally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prevascar 250ng
Description: • 100uL of 250ng/100uL Prevascar per linear centimetre wound margin injected intradermally.
Study: NCT04735328

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CT-PTSD
Description: CT-PTSD (Cognitive Therapy for PTSD), treatment method developed for treating patients with Post Traumatic Stress Symptoms (PTSD).

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: EMDR
Description: EMDR (Eye Movement and Desensitization Reprocessing), treatment method developed for treating patients with Post-Traumatic Stress Symptoms (PTSD).
Study: NCT03318835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide combined with R-CHOP
Description: rituximab 375 mg/m2,ivgtt D1 cyclophosphamide 750 mg/m2 iv D2 vincristine 1.4 mg/m2 \[capped at 2.0 mg\], iv D2 doxorubicin 50 mg/m2 iv D2 prednisone 100 mg/m2 per day PO D2-6 Thalidomide 200mg PO QN D1-21

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R-CHOP
Description: rituximab 375 mg/m2,ivgtt D1 cyclophosphamide 750 mg/m2 iv D2 vincristine 1.4 mg/m2 \[capped at 2.0 mg\], iv D2 doxorubicin 50 mg/m2 iv D2 prednisone 100 mg/m2 per day PO D2-6
Study: NCT03315520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: BeEAC conditioning regimen:~bendamustine 200 mg/м2 D-6 - D-5; cytarabine 400 mg/м2 D-4 - D-1; etoposide 400 mg/м2 D-4 - D-1; cyclophosphamide 140 mg/м2 totally, divided in 4 days (D-4 - D-1)
Study: NCT01507688

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stroke Self-Management
Description: Stroke self-management program- Participants randomized to this program will receive 6 bi-weekly telephone sessions during the first 3 months followed by 3 monthly reinforcement telephone sessions coupled with 3 monthly group sessions during months 4-6.
Study: NCT04674007

Intervention type: OTHER
Intervention: 3D analysis of landing task
Description: Landing tasks (anticipated, unanticipated and cognitive dual task) are investigated with 3D analysis by using an opto-electronic system
Study: NCT03726957

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Improved Cookstoves
Description: Villages were randomized to have participating households assigned to either a traditional biomass burning cookstove or to an improved cookstove. Once the participating villages had been selected, the investigators used their list of eligible households within each village to randomly order these households. Within each village, the investigators then approached the eligible households in the order that had been randomly chosen and continued that process until four households within each village had agreed to participate. The selection of villages and households preceded randomization and was pursued with the clear understanding that group assignment would be random, and that participation reflected a willingness to be randomized to either study group.
Study: NCT02019732

Intervention type: OTHER
Intervention: Data collection
Description: Data collection from existing electronic healthcare databases (Marketscan Commercial database, MarketScan Medicare Supplemental database).
Study: NCT01544920

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: peg-Interferon alfa-2a
Description: peg-IFN (180 ug) was taken once weekly via subcutaneous injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: peg-Interferon alfa-2a
Description: peg-IFN (180 ug) was taken once weekly via subcutaneous injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: RBV 200 mg tablets taken by mouth at a total daily dose of 1,000 mg (body weight \<75 kilograms \[kg\]) or 1,200 mg (body weight ≥75 kg) with total daily dose divided into 2 dosings.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: RBV 200 mg tablets taken by mouth at a total daily dose of 1,000 mg (body weight \<75 kilograms \[kg\]) or 1,200 mg (body weight ≥75 kg) with total daily dose divided into 2 dosings.
Study: NCT00363909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: citalopram hydrobromide
Study: NCT01544920

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Boceprevir
Description: Four 200 mg BOC capsules taken three times a day by mouth for a total daily dose of 2,400 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boceprevir
Description: Four 200 mg BOC capsules taken three times a day by mouth for a total daily dose of 2,400 mg.
Study: NCT03242694

Intervention type: DIAGNOSTIC_TEST
Intervention: LA pressure, voltage map, strain, scar-map, blood sampling
Description: invasive LA pressure monitoring, LA voltage map creation, LA strain evaluation by transthoracal echocardiography, LA scar-mapping by cardiac MRI, defining biomarkers from blood samples during atrial fibrillation and after pulmonary vein isolation in sinus rhythm

Intervention type: PROCEDURE
Intervention: pulmonary vein isolation
Description: pulmonary vein isolation without creating additional ablation lesions
Study: NCT01412528

Intervention type: OTHER
Group type: OTHER
Intervention: Allergen extracts
Study: NCT01648634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebivolol
Description: A 1.25mg-test dose will be administrated to assess the treatment tolerance before randomization. A forced titration of nebivolol will be performed with 2 weeks periods. Full dose of nebivolol is 5mg/day (7.5mg/day for patients whose weight is\>60kg)
Study: NCT00363909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: citalopram hydrobromide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: citalopram hydrobromide

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT01473446

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Goal directed fluid therapy guided by LiDCOrapid
Description: Standard monitoring. The patient is connected to the LiDCOrapid monitor via an arterial line placed in a.radialis. A bolus of 500 ml Ringer acetate is given before anesthesia. If the stroke volume (SV) increases more than 10%, repeat the procedure until the SV is not increasing. After that, induction of anesthesia.~Maintenance fluid is given as Ringer acetate 2ml/kg/t. Continuous monitoring of stroke volume variation (SVV). If SVV\> 10%, give a fluid bolus 6ml/kg Ringer acetate. Repeat until SVV \<10%. Bleeding is being replaced 1:1 with hydroxyethyl starch. SAG by bleeding \>1000ml. By fall in blood pressure and SVV \<10%, start vasoactive treatment with epinephrine. Postoperative is given Glucose 5% 80ml/h.
Study: NCT02488538

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combined oral contraceptives
Description: Women will receive COC containing drospirenone daily for 21 days starting from the 3rd day of menstruation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combined oral contraceptives
Description: Women will receive COC containing drospirenone daily for 21 days starting from the 3rd day of menstruation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: women will receive oral fluoxetine 20 mg daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Combined oral contraceptives placebo
Description: women will receive oral placebo similar to COC daily for 21 days starting from the 3rd day of menstruation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine placebo
Description: women will receive a daily oral placebo similar in size, color and structure to fluoxetine.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluoxetine placebo
Description: women will receive a daily oral placebo similar in size, color and structure to fluoxetine.
Study: NCT01648634

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A 1.25mg-test dose of nebivolol will be administrated to assess the treatment tolerance before randomization. A forced titration of placebo will be performed with 2 weeks periods. Full dose of placebo is 5mg/day (7.5mg/day for patients whose weight is\>60kg)
Study: NCT00302341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pafuramidine maleate (DB289)
Description: Oral tablet, 100 mg bid, 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trimethoprim-Sulfamethoxazole (TMP-SMX)
Description: 15 mg/kg, oral tablet split tid X 21 days
Study: NCT04499937

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Streak incentive
Description: Participants will receive prompts 3 times a day for 21 days prompting them to complete surveys. They will start with a $0 balance and will earn a fixed amount for each response.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Loss-based incentive
Description: Participants will receive prompts 3 times a day for 21 days prompting them to complete surveys. They will start with the maximum balance and will lose a fixed amount for each response they do not complete.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Flat-fee control status quo condition
Description: Participants will receive prompts 3 times a day for 21 days prompting them to complete surveys. They will receive the maximum compensation at the end of the study.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Flat-Fitbit control status quo condition
Description: Participants will receive prompts 3 times a day for 21 days prompting them to complete surveys. They will keep the Fitbit at the end of the study.
Study: NCT02488538

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Daily record of severity of problems
Description: Women will record their symptoms daily using the daily record of severity of symptoms.
Study: NCT01765530

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ETT cleaning maneuver
Description: EndOclear device will be used for ETT cleaning maneuver. This is a commercially available device. It consists of an ETT cleaning apparatus with a flexible central tube and a cleaning device at its distal end. The cleaning device has a mechanically expandable mesh structure which can be adapted to selectively move between a radially-collapsed position and a radially-expanded one. In operation, the collapsed cleaning apparatus is inserted into the ETT through a Y-shaped connector. The device is then expanded by a safety toggle protected trigger mechanism that, when fired, presses the device's smooth silicone disc against the inside surface of the ETT. The cleaning apparatus is then pulled out of the ETT removing mucus deposits and secretions.~We will add endOclear to the standard ICU practice, scheduling the systematic use of the device every 8 hours for the whole intubation period.
Study: NCT00413556

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ALK Grass tablet

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: ALK Grass tablet
Study: NCT02029937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proflavine, high resolution imaging
Description: 5-10 ml of proflavine hemisulfate (0.01%) will be sprayed on the esophageal mucosa. The HRME will then be inserted through the endoscope and gently placed against the mucosa. Imaging of abnormal tissues will be performed.
Study: NCT04007133

Intervention type: OTHER
Intervention: Girerd test
Description: This is a simple and quick questionnaire, composed of 6 questions with a binary yes/no answer. It allows to assess the degree of compliance with the prescribed treatment to better identify the constraints related to the treatment.
Study: NCT02097290

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRT-D
Description: For all subjects with the AUTOGEN CRT-D, the autothreshold algorithms will be evaluated
Study: NCT01654380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2605541
Description: LY2605541 is a solution. The concentration of LY2605541 is 100 units/milliliter (U/mL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2605541
Description: LY2605541 is a solution. The concentration of LY2605541 is 100 units/milliliter (U/mL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2605541
Description: LY2605541 is a solution. The concentration of LY2605541 is 100 units/milliliter (U/mL).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine
Description: Insulin glargine is a 100 U/mL solution in 10 milliliter (mL) glass vial.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine
Description: Insulin glargine is a 100 U/mL solution in 10 milliliter (mL) glass vial.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine
Description: Insulin glargine is a 100 U/mL solution in 10 milliliter (mL) glass vial.
Study: NCT02348268

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Therapy
Description: The manual therapy techniques included: (i) anterior-posterior and side-shift of the cervical spine; (ii) muscle energy technique involving side-bending of cervical spine; (iii) neuromuscular technique for restricted C1-C2 rotation; (iv) inhibitive occipital distraction; and (v) cervical stretching: post-isometric relaxation for the upper trapezius, scalene and sternocleidomastoid muscles.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial Release Therapy
Description: The myofascial release therapy techniques included: (i) cranial base release, adjusting the relation of the rectus capitis posterior muscles to the dura mater; (ii) gross release of the sternocleidomastoid muscle; (iii) release of the suprahyoid and infrahyoid muscles; and (iv) release of the retrohyoid fascia.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Analgesic therapy
Description: Analgesic therapy consisted of superficial thermotherapy by an infrared lamp (Infra 2000, Enraf Nonius) and TENS (TENSMED 911, Enraf Nonius). The 250-watts infrared lamp was focused at a distance of 50 cm on the cervical area for 15 minutes. TENS employed 80 Hz frequency, 150 µs pulse duration, with 50x50 mm electrodes (Gel-Trode, Enraf Nonius) placed on the painful or metamers areas for 20 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Analgesic therapy
Description: Analgesic therapy consisted of superficial thermotherapy by an infrared lamp (Infra 2000, Enraf Nonius) and TENS (TENSMED 911, Enraf Nonius). The 250-watts infrared lamp was focused at a distance of 50 cm on the cervical area for 15 minutes. TENS employed 80 Hz frequency, 150 µs pulse duration, with 50x50 mm electrodes (Gel-Trode, Enraf Nonius) placed on the painful or metamers areas for 20 minutes.
Study: NCT05084781

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coblation Debridement (FLOW90)
Description: bipolar radiofrequency energy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coblation Debridement (FLOW90)
Description: bipolar radiofrequency energy
Study: NCT02488538

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Daily record of severity of problems
Description: Women will record their symptoms daily using the daily record of severity of symptoms.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Daily record of severity of problems
Description: Women will record their symptoms daily using the daily record of severity of symptoms.
Study: NCT01895101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 gr tranexamic acid
Description: This group receives pericardial lavage with 2 gr tranexamic diluted in 200 ml normothermic saline solution (NaCl 0.9%).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: This group receives pericardial lavage with 200 ml normothermic saline solution without tranexamic acid
Study: NCT02663518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-0791800 (TTI-621)
Description: Monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-0791800 (TTI-621)
Description: Monotherapy
Study: NCT04168658

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Physical activity and education intervention
Description: At least six staff from each nursing home that assigned to the intervention group will be invited to attend two educational workshops. Participants in the intervention group will receive the following interventions.~1. Face-to-face workshops: Five 1-hour educational workshops on physical activity will be delivered in months 1, 3, 5, 7 and 9 of the program held at each nursing home.~2. Booklet: At the first educational workshop, each participant will be provided with a pictorial booklet.~3. Exercise: The physical activity training consists of 50-60 min exercise sessions three times a week on non-consecutive days for 12 months.~4. Others (newsletters, phone calls, and reminders): The intervention group will also receive newsletters containing myth dispelling information on osteoporosis and physical activity, motivational phone calls and a total of 52 SMS via mobile phones (reminders to attend workshop sessions and physical activity motivating messages) over 12 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education intervention
Description: Participants in the control group will only receive educational materials (i.e. face-to-face workshops and booklet) and will be wait listed to receive no other interventions of this study until after the post-intervention.
Study: NCT00997958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Dose escalation increasing successively from 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, and 5.0 grams p.o. bid.~Each patient will be treated for eight weeks (56 days).
Study: NCT05291793

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenoxicam 20 Mg Powder for Solution for Injection Vial
Description: Tenoxicam 20 Mg Powder is mixed with dissolving solvent then administered intraarticularly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Methylprednisolone 40 Mg (suspension) administered intraarticularly

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Saline
Description: 2ml sterile saline administered intraarticularly
Study: NCT02931032

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sampling of dental plaque / infected dentine
Description: A sample of dental plaque / infected dentine will be taken during routine dental treatment and cultivated in a lab. The headspace above the culture will be sampled and analyzed in GC-MS for the detection of unique volatile organic compounds emitted by the plaque components.
Study: NCT01453140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide and Sirolimus
Description: On the first day of treatment, cyclophosphamide will be administered at a dose of 4g/m2 IV x 1 dose. Patients who are \>40% above ideal weight will be dosed based on adjusted weight and adjusted BSA.~One day after the administration of cyclophosphamide, patients will receive sirolimus 6 mg PO x 1 and on the following day will start sirolimus at a dose of 2 mg PO daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose IL-2 with Cytoxan + Sirolimus
Description: Patients in treatment arm B will be receiving low-dose IL-2 in conjunction with the cyclophosphamide and sirolimus.~IL-2 will be administered at a dose of 0.5E6 IU/m2 SQ daily x 8 weeks followed by 4 weeks off, starting 14 days after the cyclophosphamide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose IL-2, low dose Vidaza, cyclophosphamide & Sirolimus
Description: Patients in treatment arm C will be receiving low-dose azacitidine (Vidaza). The Vidaza will be initiated between day 27 and 32 following the cyclophosphamide.~The dose administered will be 10 mg SQ daily for 5 days followed by 3 weeks off.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide and Sirolimus
Description: Day 1: Cyclophosphamide Day 2: Sirolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose IL-2 with Cytoxan + Sirolimus
Description: treatment arm B will be receiving low-dose IL-2 in conjunction with the cyclophosphamide and sirolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose IL-2, Vidaza, Cytoxan & Sirolimus
Description: Vidaza will be initiated between day 27 and 32 following the cyclophosphamide.
Study: NCT03847766

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PRO-based follow-up
Description: Diagnose specific questionnaires are used to screen patients in need of contact to the outpatient clinic

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PRO-based telephone consultation
Description: diagnose-specific questionnaires are used to support communication between clinician and patient during a phone consultation